Fractyl Health has named Mike Zumdahl as Senior Vice President of Market Access and Commercial Strategy to prepare for the upcoming REMAIN-1 pivotal cohort topline data expected in early Q4 2026. Zumdahl brings extensive experience from Inari Medical and Novo Nordisk, where he developed market access strategies for breakthrough therapies. His role will focus on building reimbursement and health economic infrastructure for Revita®, a novel endoscopic procedure targeting weight maintenance after GLP-1 therapy discontinuation. This appointment positions Fractyl to advance commercialization efforts as it anticipates a potential De Novo marketing application submission for Revita® later in 2026.
Bitcoin miners are experiencing declining revenue as the network's hash rate and mining difficulty fall, reflecting a shift of miners into AI infrastructure. Despite this stress, miners are accumulating Bitcoin, with reserves increasing by 1%, signal...
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
